{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:53:56Z","timestamp":1788317636261,"version":"build-2803163510"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02466-4","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:31:19Z","timestamp":1727170279000},"page":"483-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-9562","authenticated-orcid":false,"given":"Mahmoud","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Abosheaishaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"issue":"Suppl 1","key":"2466_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","volume":"33","author":"JH Chun","year":"2020","unstructured":"Chun JH, Butts A (2020) Long-acting GLP-1RAs: an overview of efficacy, safety, and their role in type 2 diabetes management. JAAPA 33(Suppl 1):3\u201318","journal-title":"JAAPA"},{"issue":"4","key":"2466_CR2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like Peptide-1. Cell Metab 27(4):740\u2013756","journal-title":"Cell Metab"},{"issue":"8","key":"2466_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","volume":"16","author":"J Seufert","year":"2014","unstructured":"Seufert J, Gallwitz B (2014) The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 16(8):673\u2013688","journal-title":"Diabetes Obes Metab"},{"key":"2466_CR4","doi-asserted-by":"crossref","first-page":"105782","DOI":"10.1016\/j.phrs.2021.105782","volume":"171","author":"E Lazzaroni","year":"2021","unstructured":"Lazzaroni E et al (2021) Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res 171:105782","journal-title":"Pharmacol Res"},{"issue":"5","key":"2466_CR5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jcjd.2017.08.242","volume":"41","author":"JA Lovshin","year":"2017","unstructured":"Lovshin JA (2017) Glucagon-like Peptide-1 receptor agonists: a Class Update for treating type 2 diabetes. Can J Diabetes 41(5):524\u2013535","journal-title":"Can J Diabetes"},{"issue":"2","key":"2466_CR6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1574886315999201208212356","volume":"16","author":"AM Iqbal","year":"2021","unstructured":"Iqbal AM et al (2021) Efficacy and Cardiovascular Safety of GLP-1 receptor analogues. Curr Drug Saf 16(2):197\u2013206","journal-title":"Curr Drug Saf"},{"issue":"3","key":"2466_CR7","doi-asserted-by":"crossref","first-page":"e13663","DOI":"10.1111\/obr.13663","volume":"25","author":"RM Goldenberg","year":"2024","unstructured":"Goldenberg RM et al (2024) Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists. Obes Rev 25(3):e13663","journal-title":"Obes Rev"},{"issue":"3","key":"2466_CR8","doi-asserted-by":"crossref","first-page":"e13547","DOI":"10.1111\/1753-0407.13547","volume":"16","author":"M Nassar","year":"2024","unstructured":"Nassar M, Misra A, Bloomgarden Z (2024) Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: a retrospective comparative effectiveness study based on a global TriNetX health research database. J Diabetes 16(3):e13547","journal-title":"J Diabetes"},{"issue":"9","key":"2466_CR9","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","volume":"60","author":"A Vinue","year":"2017","unstructured":"Vinue A et al (2017) The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia 60(9):1801\u20131812","journal-title":"Diabetologia"},{"issue":"21","key":"2466_CR10","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","volume":"124","author":"Z Shah","year":"2011","unstructured":"Shah Z et al (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 124(21):2338\u20132349","journal-title":"Circulation"},{"issue":"4","key":"2466_CR11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db10-1338","volume":"60","author":"J Shirakawa","year":"2011","unstructured":"Shirakawa J et al (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60(4):1246\u20131257","journal-title":"Diabetes"},{"key":"2466_CR12","doi-asserted-by":"crossref","unstructured":"Sawada N et al (2020) Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis. J Diabetes Res, 2020: p. 8843310","DOI":"10.1155\/2020\/8843310"},{"issue":"4","key":"2466_CR13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","volume":"53","author":"I Hadjiyanni","year":"2010","unstructured":"Hadjiyanni I et al (2010) Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53(4):730\u2013740","journal-title":"Diabetologia"},{"issue":"1","key":"2466_CR14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/icb.2010.70","volume":"89","author":"G Liu","year":"2011","unstructured":"Liu G et al (2011) Phenotypic and functional switch of macrophages induced by regulatory CD4\u2009+\u2009CD25\u2009+\u2009T cells in mice. Immunol Cell Biol 89(1):130\u2013142","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"2466_CR15","first-page":"3573","volume":"17","author":"S Wan","year":"2019","unstructured":"Wan S, Sun H (2019) Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway. Exp Ther Med 17(5):3573\u20133579","journal-title":"Exp Ther Med"},{"key":"2466_CR16","doi-asserted-by":"crossref","unstructured":"Yang L et al (2021) Effect of GLP-1\/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis. Mediators Inflamm, 2021: p. 5568159","DOI":"10.1155\/2021\/5568159"},{"issue":"3","key":"2466_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cea.12860","volume":"47","author":"PD Mitchell","year":"2017","unstructured":"Mitchell PD et al (2017) Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin Exp Allergy 47(3):331\u2013338","journal-title":"Clin Exp Allergy"},{"key":"2466_CR18","unstructured":"Kamuthachad L et al (2021) Invariant natural killer T (iNKT) cells response in human melioidosis. Asian Pac J Allergy Immunol"},{"issue":"1","key":"2466_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","volume":"171","author":"M Buysschaert","year":"2014","unstructured":"Buysschaert M et al (2014) Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal gammadelta T-cell number: a prospective case-series study. Br J Dermatol 171(1):155\u2013161","journal-title":"Br J Dermatol"},{"issue":"1","key":"2466_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2011.03506.x","volume":"135","author":"E Moens","year":"2012","unstructured":"Moens E, Veldhoen M (2012) Epithelial barrier biology: good fences make good neighbours. Immunology 135(1):1\u20138","journal-title":"Immunology"},{"key":"2466_CR21","doi-asserted-by":"crossref","unstructured":"Yusta B et al (2015) GLP-1R agonists modulate enteric Immune responses through the intestinal intraepithelial lymphocyte GLP-1R. 64(7):2537\u20132549Diabetes","DOI":"10.2337\/db14-1577"},{"issue":"1","key":"2466_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.23876\/j.krcp.21.014","volume":"41","author":"E Choi","year":"2022","unstructured":"Choi E et al (2022) The effect of probiotic supplementation on systemic inflammation in dialysis patients. Kidney Res Clin Pract 41(1):89\u2013101","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"2466_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/imr.12170","volume":"259","author":"KS Smigiel","year":"2014","unstructured":"Smigiel KS et al (2014) Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev 259(1):40\u201359","journal-title":"Immunol Rev"},{"issue":"1","key":"2466_CR24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","volume":"1150","author":"S Xue","year":"2008","unstructured":"Xue S et al (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci 1150(1):152\u2013156","journal-title":"Ann N Y Acad Sci"},{"key":"2466_CR25","doi-asserted-by":"crossref","unstructured":"Chiou HC et al (2019) Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the Central Nervous System. Int J Mol Sci, 20(7)","DOI":"10.3390\/ijms20071584"},{"issue":"22","key":"2466_CR26","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1073\/pnas.1415675112","volume":"112","author":"SN Harbour","year":"2015","unstructured":"Harbour SN et al (2015) Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci U S A 112(22):7061\u20137066","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2466_CR27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","volume":"12","author":"K Hirota","year":"2011","unstructured":"Hirota K et al (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12(3):255\u2013263","journal-title":"Nat Immunol"},{"issue":"9","key":"2466_CR28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jdiacomp.2017.05.013","volume":"31","author":"A Itoh","year":"2017","unstructured":"Itoh A et al (2017) GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. J Diabetes Complications 31(9):1370\u20131375","journal-title":"J Diabetes Complications"},{"issue":"2","key":"2466_CR29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ajpath.2019.10.008","volume":"190","author":"F Moschovaki Filippidou","year":"2020","unstructured":"Moschovaki Filippidou F et al (2020) Glucagon-like Peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-Cell proliferation. Am J Pathol 190(2):400\u2013411","journal-title":"Am J Pathol"},{"key":"2466_CR30","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF et al (2023) Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol 14:1148209","journal-title":"Front Immunol"},{"key":"2466_CR31","doi-asserted-by":"crossref","first-page":"105969","DOI":"10.1016\/j.intimp.2019.105969","volume":"77","author":"C Lu","year":"2019","unstructured":"Lu C et al (2019) Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. Int Immunopharmacol 77:105969","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"2466_CR32","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1210\/jc.2019-00296","volume":"104","author":"FA Shah","year":"2019","unstructured":"Shah FA et al (2019) Therapeutic effects of endogenous incretin hormones and exogenous incretin-based medications in Sepsis. J Clin Endocrinol Metab 104(11):5274\u20135284","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2466_CR33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","volume":"110","author":"S Steven","year":"2015","unstructured":"Steven S et al (2015) Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia. Basic Res Cardiol 110(2):6","journal-title":"Basic Res Cardiol"},{"key":"2466_CR34","doi-asserted-by":"crossref","first-page":"706908","DOI":"10.3389\/fphar.2021.706908","volume":"12","author":"F Yang","year":"2021","unstructured":"Yang F et al (2021) GLP-1 receptor: a New Target for Sepsis. Front Pharmacol 12:706908","journal-title":"Front Pharmacol"},{"key":"2466_CR35","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti G et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res 182:106320","journal-title":"Pharmacol Res"},{"issue":"8","key":"2466_CR36","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/antiox10081175","volume":"10","author":"J Helmstadter","year":"2021","unstructured":"Helmstadter J et al (2021) GLP-1 Analog Liraglutide improves vascular function in Polymicrobial Sepsis by reduction of oxidative stress and inflammation. Antioxid (Basel) 10(8):1175","journal-title":"Antioxid (Basel)"},{"issue":"6","key":"2466_CR37","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.3892\/etm.2016.3255","volume":"11","author":"CH Lin","year":"2016","unstructured":"Lin CH, Lin CC (2016) Sitagliptin attenuates in fl ammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-kappab pathway inhibition. Exp Ther Med 11(6):2609\u20132615","journal-title":"Exp Ther Med"},{"issue":"6","key":"2466_CR38","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M et al (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab 36(6):1302\u20131319e12","journal-title":"Cell Metab"},{"issue":"2","key":"2466_CR39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1874609808666150727110744","volume":"8","author":"P Chalan","year":"2015","unstructured":"Chalan P et al (2015) Rheumatoid arthritis, Immunosenescence and the hallmarks of Aging. Curr Aging Sci 8(2):131\u2013146","journal-title":"Curr Aging Sci"},{"key":"2466_CR40","doi-asserted-by":"crossref","first-page":"nzaa063004","DOI":"10.1093\/cdn\/nzaa063_004","volume":"4","author":"E Baah","year":"2020","unstructured":"Baah E (2020) Obesity and arthritis. Curr Developments Nutr 4:nzaa063004","journal-title":"Curr Developments Nutr"},{"key":"2466_CR41","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.intimp.2019.105732","volume":"75","author":"X Du","year":"2019","unstructured":"Du X et al (2019) The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 75:105732","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"2466_CR42","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/iub.2031","volume":"71","author":"Y Tao","year":"2019","unstructured":"Tao Y et al (2019) Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life 71(7):969\u2013977","journal-title":"IUBMB Life"},{"key":"2466_CR43","doi-asserted-by":"crossref","first-page":"105649","DOI":"10.1016\/j.intimp.2019.05.034","volume":"74","author":"W Zheng","year":"2019","unstructured":"Zheng W et al (2019) Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol 74:105649","journal-title":"Int Immunopharmacol"},{"key":"2466_CR44","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T et al (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther 2:17023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2466_CR45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00109-011-0748-0","volume":"89","author":"A Salminen","year":"2011","unstructured":"Salminen A, Hyttinen JM, Kaarniranta K (2011) AMP-activated protein kinase inhibits NF-\u03baB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 89(7):667\u2013676","journal-title":"J Mol Med (Berl)"},{"key":"2466_CR46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","volume":"107","author":"J Yang","year":"2019","unstructured":"Yang J, Wang Z, Zhang X (2019) GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol 107:124\u2013128","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"2466_CR47","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/ker349","volume":"51","author":"VM Bhole","year":"2012","unstructured":"Bhole VM et al (2012) Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 51(3):552\u2013556","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2466_CR48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","volume":"51","author":"A Faurschou","year":"2014","unstructured":"Faurschou A et al (2014) Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 51(1):147\u2013150","journal-title":"Acta Diabetol"},{"issue":"6","key":"2466_CR49","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.mehy.2011.09.011","volume":"77","author":"A Faurschou","year":"2011","unstructured":"Faurschou A et al (2011) Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? Med Hypotheses 77(6):1098\u20131101","journal-title":"Med Hypotheses"},{"key":"2466_CR50","doi-asserted-by":"crossref","unstructured":"Gaudreau M et al (2023) POS1133 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH UPADACITINIB RESULTS IN THE COORDINATED INHIBITION OF TYPE 1 IFN-RELATED BIOMARKERS: BIOMARKER ANALYSIS OF THE M19-130 (SLEEK) PHASE 2 STUDY. BMJ Publishing Group Ltd.","DOI":"10.1136\/annrheumdis-2023-eular.4002"},{"key":"2466_CR51","doi-asserted-by":"crossref","unstructured":"Aggarwal R et al (2023) AB0144 PHARMACOLOGICAL CHARACTERIZATION OF GLPG3667, A SELECTIVE TYK2 INHIBITOR, SUPPORTS DEVELOPMENT IN DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS. BMJ Publishing Group Ltd","DOI":"10.1136\/annrheumdis-2023-eular.3603"},{"issue":"4","key":"2466_CR52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jphs.2021.02.002","volume":"145","author":"M Dulak-Lis","year":"2021","unstructured":"Dulak-Lis M et al (2021) A novel JAK\/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus. J Pharmacol Sci 145(4):340\u2013348","journal-title":"J Pharmacol Sci"},{"key":"2466_CR53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molimm.2021.08.015","volume":"139","author":"R Dou","year":"2021","unstructured":"Dou R et al (2021) Mesenchymal stem cell exosomal tsRNA-21109 alleviate systemic lupus erythematosus by inhibiting macrophage M1 polarization. Mol Immunol 139:106\u2013114","journal-title":"Mol Immunol"},{"issue":"3","key":"2466_CR54","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"SE Arnold","year":"2018","unstructured":"Arnold SE et al (2018) Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 14(3):168\u2013181","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2466_CR55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","volume":"136","author":"WA Banks","year":"2012","unstructured":"Banks WA, Owen JB, Erickson MA (2012) Insulin in the brain: there and back again. Pharmacol Ther 136(1):82\u201393","journal-title":"Pharmacol Ther"},{"key":"2466_CR56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","volume":"97","author":"M Golpich","year":"2015","unstructured":"Golpich M et al (2015) Glycogen synthase kinase-3 beta (GSK-3beta) signaling: implications for Parkinson\u2019s disease. Pharmacol Res 97:16\u201326","journal-title":"Pharmacol Res"},{"key":"2466_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","volume":"118","author":"F Bassil","year":"2014","unstructured":"Bassil F et al (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 118:1\u201318","journal-title":"Prog Neurobiol"},{"key":"2466_CR58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","volume":"16","author":"D Cheng","year":"2022","unstructured":"Cheng D et al (2022) The role of Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases. Drug Des Devel Ther 16:665\u2013684","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2466_CR59","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41467-020-14934-5","volume":"11","author":"F Wu","year":"2020","unstructured":"Wu F et al (2020) Full-length human GLP-1 receptor structure without orthosteric ligands. Nat Commun 11(1):1272","journal-title":"Nat Commun"},{"key":"2466_CR60","doi-asserted-by":"crossref","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS et al (2020) Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol 180:114187","journal-title":"Biochem Pharmacol"},{"key":"2466_CR61","doi-asserted-by":"crossref","unstructured":"Jantrapirom S et al (2020) Liraglutide suppresses tau hyperphosphorylation, amyloid Beta Accumulation through regulating neuronal insulin signaling and BACE-1 activity. Int J Mol Sci, 21(5)","DOI":"10.3390\/ijms21051725"},{"issue":"1","key":"2466_CR62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","volume":"245","author":"AF Batista","year":"2018","unstructured":"Batista AF et al (2018) The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J Pathol 245(1):85\u2013100","journal-title":"J Pathol"},{"key":"2466_CR63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diabres.2016.10.024","volume":"124","author":"J Zhang","year":"2017","unstructured":"Zhang J et al (2017) An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer\u2019s disease. Diabetes Res Clin Pract 124:41\u201347","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2466_CR64","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.sjbs.2019.12.028","volume":"27","author":"RL Jayaraj","year":"2020","unstructured":"Jayaraj RL, Azimullah S, Beiram R (2020) Diabetes as a risk factor for Alzheimer\u2019s disease in the Middle East and its shared pathological mediators. Saudi J Biol Sci 27(2):736\u2013750","journal-title":"Saudi J Biol Sci"},{"issue":"11","key":"2466_CR65","doi-asserted-by":"crossref","first-page":"e7917","DOI":"10.1371\/journal.pone.0007917","volume":"4","author":"YD Ke","year":"2009","unstructured":"Ke YD et al (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer\u2019s disease. PLoS ONE 4(11):e7917","journal-title":"PLoS ONE"},{"issue":"9","key":"2466_CR66","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar D, Craft S (2020) Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol 19(9):758\u2013766","journal-title":"Lancet Neurol"},{"issue":"10","key":"2466_CR67","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00259-019-04409-1","volume":"46","author":"A Ciarmiello","year":"2019","unstructured":"Ciarmiello A et al (2019) Longitudinal cognitive decline in mild cognitive impairment subjects with early amyloid-beta neocortical deposition. Eur J Nucl Med Mol Imaging 46(10):2090\u20132098","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2466_CR68","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A et al (2017) Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain 140(12):3286\u20133300","journal-title":"Brain"},{"issue":"2","key":"2466_CR69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12264-013-1424-x","volume":"30","author":"DJ Bonda","year":"2014","unstructured":"Bonda DJ et al (2014) Neuronal failure in Alzheimer\u2019s disease: a view through the oxidative stress looking-glass. Neurosci Bull 30(2):243\u2013252","journal-title":"Neurosci Bull"},{"issue":"1","key":"2466_CR70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-017-0379-z","volume":"24","author":"W Ahmad","year":"2017","unstructured":"Ahmad W et al (2017) Oxidative toxicity in diabetes and Alzheimer\u2019s disease: mechanisms behind ROS\/ RNS generation. J Biomed Sci 24(1):76","journal-title":"J Biomed Sci"},{"issue":"3","key":"2466_CR71","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1471-4159.2005.03615.x","volume":"96","author":"J Wang","year":"2006","unstructured":"Wang J, Markesbery WR, Lovell MA (2006) Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96(3):825\u2013832","journal-title":"J Neurochem"},{"key":"2466_CR72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4939-2627-5_9","volume":"1303","author":"A Grimm","year":"2016","unstructured":"Grimm A, Schmitt K, Eckert A (2016) Advanced Mitochondrial Respiration Assay for Evaluation of Mitochondrial Dysfunction in Alzheimer\u2019s Disease. Methods Mol Biol 1303:171\u2013183","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2466_CR73","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s11064-017-2182-3","volume":"42","author":"GE Gibson","year":"2017","unstructured":"Gibson GE, Thakkar A (2017) Interactions of Mitochondria\/Metabolism and Calcium Regulation in Alzheimer\u2019s Disease: a Calcinist Point of View. Neurochem Res 42(6):1636\u20131648","journal-title":"Neurochem Res"},{"key":"2466_CR74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mcn.2019.06.009","volume":"98","author":"PJ Flannery","year":"2019","unstructured":"Flannery PJ, Trushina E (2019) Mitochondrial dynamics and transport in Alzheimer\u2019s disease. Mol Cell Neurosci 98:109\u2013120","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"2466_CR75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","volume":"40","author":"JS Kerr","year":"2017","unstructured":"Kerr JS et al (2017) Mitophagy and Alzheimer\u2019s Disease: Cellular and Molecular mechanisms. Trends Neurosci 40(3):151\u2013166","journal-title":"Trends Neurosci"},{"issue":"6","key":"2466_CR76","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/febs.14332","volume":"285","author":"Y Gerakis","year":"2018","unstructured":"Gerakis Y, Hetz C (2018) Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer\u2019s disease. FEBS J 285(6):995\u20131011","journal-title":"FEBS J"},{"issue":"2","key":"2466_CR77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.gene.2016.05.018","volume":"587","author":"X Zhang","year":"2016","unstructured":"Zhang X et al (2016) Endoplasmic reticulum stress mediates JNK-dependent IRS-1 serine phosphorylation and results in tau hyperphosphorylation in amyloid beta oligomer-treated PC12 cells and primary neurons. Gene 587(2):183\u2013193","journal-title":"Gene"},{"issue":"6","key":"2466_CR78","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358\u2013372","journal-title":"Nat Rev Neurosci"},{"issue":"15","key":"2466_CR79","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1073\/pnas.1000645107","volume":"107","author":"S Takeda","year":"2010","unstructured":"Takeda S et al (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107(15):7036\u20137041","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2466_CR80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1750-1326-6-85","volume":"6","author":"Y Mu","year":"2011","unstructured":"Mu Y, Gage FH (2011) Adult hippocampal neurogenesis and its role in Alzheimer\u2019s disease. Mol Neurodegener 6:85","journal-title":"Mol Neurodegener"},{"issue":"12","key":"2466_CR81","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","volume":"34","author":"E Cereda","year":"2011","unstructured":"Cereda E et al (2011) Diabetes and risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Diabetes Care 34(12):2614\u20132623","journal-title":"Diabetes Care"},{"key":"2466_CR82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbr.2018.05.025","volume":"351","author":"S Sharma","year":"2018","unstructured":"Sharma S, Taliyan R (2018) High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats. Behav Brain Res 351:17\u201323","journal-title":"Behav Brain Res"},{"key":"2466_CR83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fnins.2018.00073","volume":"12","author":"L Yang","year":"2018","unstructured":"Yang L et al (2018) The role of Insulin\/IGF-1\/PI3K\/Akt\/GSK3beta signaling in Parkinson\u2019s Disease Dementia. Front Neurosci 12:73","journal-title":"Front Neurosci"},{"key":"2466_CR84","doi-asserted-by":"crossref","unstructured":"Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol, 106\u2013107: p. 17\u201332","DOI":"10.1016\/j.pneurobio.2013.04.004"},{"key":"2466_CR85","doi-asserted-by":"crossref","unstructured":"Hong CT et al (2020) Insulin Resistance Promotes Parkinson\u2019s Disease through Aberrant Expression of alpha-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling. Cells, 9(3)","DOI":"10.3390\/cells9030740"},{"key":"2466_CR86","doi-asserted-by":"crossref","unstructured":"Costa CAD et al (2020) The Endoplasmic Reticulum Stress\/Unfolded Protein Response and Their Contributions to Parkinson\u2019s Disease Physiopathology. Cells, 9(11)","DOI":"10.3390\/cells9112495"},{"key":"2466_CR87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2013.11.001","volume":"251","author":"L Wang","year":"2014","unstructured":"Wang L et al (2014) Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp Neurol 251:22\u201329","journal-title":"Exp Neurol"},{"issue":"4","key":"2466_CR88","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol 8(4):382\u2013397","journal-title":"Lancet Neurol"},{"issue":"3","key":"2466_CR89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00018-012-1062-x","volume":"70","author":"F Marxreiter","year":"2013","unstructured":"Marxreiter F, Regensburger M, Winkler J (2013) Adult neurogenesis in Parkinson\u2019s disease. Cell Mol Life Sci 70(3):459\u2013473","journal-title":"Cell Mol Life Sci"},{"key":"2466_CR90","doi-asserted-by":"crossref","first-page":"pe062415","DOI":"10.1002\/alz.062415","volume":"18","author":"A Atri","year":"2022","unstructured":"Atri A et al (2022) Evoke and evoke+: design of two large-scale, double\u2010blind, placebo\u2010controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer\u2019s disease. Alzheimer\u2019s Dement 18:pe062415","journal-title":"Alzheimer\u2019s Dement"},{"key":"2466_CR91","doi-asserted-by":"crossref","first-page":"1205207","DOI":"10.3389\/fphar.2023.1205207","volume":"14","author":"F Kong","year":"2023","unstructured":"Kong F et al (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: a systematic review and meta-analysis of preclinical studies. Front Pharmacol 14:1205207","journal-title":"Front Pharmacol"},{"key":"2466_CR92","doi-asserted-by":"crossref","first-page":"114578","DOI":"10.1016\/j.bcp.2021.114578","volume":"188","author":"Y Xie","year":"2021","unstructured":"Xie Y et al (2021) GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer\u2019s disease by regulating mitochondrial dysfunction via the cAMP\/PKA pathway. Biochem Pharmacol 188:114578","journal-title":"Biochem Pharmacol"},{"key":"2466_CR93","doi-asserted-by":"crossref","first-page":"101180","DOI":"10.1016\/j.molmet.2021.101180","volume":"47","author":"J Zheng","year":"2021","unstructured":"Zheng J et al (2021) GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer\u2019s disease. Mol Metab 47:101180","journal-title":"Mol Metab"},{"issue":"1","key":"2466_CR94","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s42003-021-02208-9","volume":"4","author":"Z Li","year":"2021","unstructured":"Li Z et al (2021) Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner. Commun Biol 4(1):656","journal-title":"Commun Biol"},{"issue":"1","key":"2466_CR95","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-021-01180-z","volume":"9","author":"JS Park","year":"2021","unstructured":"Park JS et al (2021) Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer\u2019s disease. Acta Neuropathol Commun 9(1):78","journal-title":"Acta Neuropathol Commun"},{"key":"2466_CR96","doi-asserted-by":"crossref","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","volume":"37","author":"M Villumsen","year":"2021","unstructured":"Villumsen M et al (2021) GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 37:100979","journal-title":"EClinicalMedicine"},{"issue":"Supplement1","key":"2466_CR97","doi-asserted-by":"crossref","first-page":"i128","DOI":"10.1093\/ecco-jcc\/jjac190.0097","volume":"17","author":"HS Christensen","year":"2023","unstructured":"Christensen HS et al (2023) DOP57 GLP-1 based therapies and risk of inflammatory bowel disease: real world evidence from a nationwide cohort study. J Crohn\u2019s Colitis 17(Supplement1):i128\u2013i128","journal-title":"J Crohn\u2019s Colitis"},{"issue":"7","key":"2466_CR98","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","volume":"203","author":"D Foer","year":"2021","unstructured":"Foer D et al (2021) Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like Peptide-1 receptor agonists. Am J Respir Crit Care Med 203(7):831\u2013840","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2466_CR99","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.202010-4017ED","volume":"203","author":"E Forno","year":"2021","unstructured":"Forno E (2021) A potential New Treatment option for Asthma in the setting of obesity or insulin resistance? Am J Respir Crit Care Med 203(7):788\u2013789","journal-title":"Am J Respir Crit Care Med"},{"key":"2466_CR100","doi-asserted-by":"crossref","first-page":"109080","DOI":"10.1016\/j.diabres.2021.109080","volume":"183","author":"A Wang","year":"2022","unstructured":"Wang A et al (2022) Association between novel glucose-lowering drugs and risk of Asthma: a network Meta-analysis of cardiorenal outcome trials. Diabetes Res Clin Pract 183:109080","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"2466_CR101","doi-asserted-by":"crossref","first-page":"e0133490","DOI":"10.1371\/journal.pone.0133490","volume":"10","author":"JG Zein","year":"2015","unstructured":"Zein JG et al (2015) Asthma is more severe in older adults. PLoS ONE 10(7):e0133490","journal-title":"PLoS ONE"},{"key":"2466_CR102","doi-asserted-by":"crossref","first-page":"102003","DOI":"10.1016\/j.pupt.2021.102003","volume":"67","author":"J Hur","year":"2021","unstructured":"Hur J et al (2021) Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model. Pulm Pharmacol Ther 67:102003","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"2466_CR103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/ACI.0000000000000797","volume":"22","author":"AY Wu","year":"2022","unstructured":"Wu AY et al (2022) Evaluating the glucagon-like peptide-1 receptor in managing asthma. Curr Opin Allergy Clin Immunol 22(1):36\u201341","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"11","key":"2466_CR104","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1111\/all.14879","volume":"76","author":"S Toki","year":"2021","unstructured":"Toki S et al (2021) Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice. Allergy 76(11):3433\u20133445","journal-title":"Allergy"},{"issue":"6","key":"2466_CR105","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc20-1794","volume":"44","author":"Y Albogami","year":"2021","unstructured":"Albogami Y et al (2021) Glucagon-like peptide 1 receptor agonists and chronic Lower Respiratory Disease exacerbations among patients with type 2 diabetes. Diabetes Care 44(6):1344\u20131352","journal-title":"Diabetes Care"},{"issue":"12","key":"2466_CR106","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.2300102","volume":"211","author":"D Foer","year":"2023","unstructured":"Foer D et al (2023) Glucagon-like Peptide-1 receptor pathway attenuates platelet activation in aspirin-exacerbated respiratory disease. J Immunol 211(12):1806\u20131813","journal-title":"J Immunol"},{"issue":"9","key":"2466_CR107","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14712598.2019.1618266","volume":"19","author":"S Mohsin","year":"2019","unstructured":"Mohsin S et al (2019) An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther 19(9):937\u2013948","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"2466_CR108","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jc.2009-0921","volume":"94","author":"KJ Hare","year":"2009","unstructured":"Hare KJ et al (2009) Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 94(12):4679\u20134687","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2466_CR109","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/JOE-17-0278","volume":"236","author":"G Mabilleau","year":"2018","unstructured":"Mabilleau G, Pereira M, Chenu C (2018) Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. J Endocrinol 236(1):R29\u2013r42","journal-title":"J Endocrinol"},{"issue":"7","key":"2466_CR110","doi-asserted-by":"crossref","first-page":"e3168","DOI":"10.1002\/dmrr.3168","volume":"35","author":"L Cheng","year":"2019","unstructured":"Cheng L et al (2019) Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 35(7):e3168","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"2466_CR111","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP15758.OR","volume":"22","author":"MP Gilbert","year":"2016","unstructured":"Gilbert MP et al (2016) Comparison of the Long-Term effects of Liraglutide and Glimepiride Monotherapy on Bone Mineral density in patients with type 2 diabetes. Endocr Pract 22(4):406\u2013411","journal-title":"Endocr Pract"},{"issue":"12","key":"2466_CR112","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","volume":"29","author":"YS Zhang","year":"2018","unstructured":"Zhang YS et al (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 29(12):2639\u20132644","journal-title":"Osteoporos Int"},{"issue":"7\u20138","key":"2466_CR113","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1002\/jcp.29261","volume":"235","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) PSMC6 promotes osteoblast apoptosis through inhibiting PI3K\/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model. J Cell Physiol 235(7\u20138):5511\u20135524","journal-title":"J Cell Physiol"},{"issue":"10","key":"2466_CR114","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41419-019-1904-7","volume":"10","author":"C Ye","year":"2019","unstructured":"Ye C et al (2019) Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K\/AKT signaling pathway. Cell Death Dis 10(10):753","journal-title":"Cell Death Dis"},{"key":"2466_CR115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2017.09.040","volume":"128","author":"Z Xie","year":"2018","unstructured":"Xie Z et al (2018) Exendin-4 attenuates neuronal death via GLP-1R\/PI3K\/Akt pathway in early brain injury after subarachnoid hemorrhage in rats. Neuropharmacology 128:142\u2013151","journal-title":"Neuropharmacology"},{"key":"2466_CR116","doi-asserted-by":"crossref","unstructured":"Ming-Yan Y et al (2019) Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K\/Akt\/caspase-3 signaling pathway. Biosci Rep, 39(8)","DOI":"10.1042\/BSR20190109"},{"issue":"2","key":"2466_CR117","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","volume":"360","author":"X Wu","year":"2017","unstructured":"Wu X et al (2017) Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase A (PKA) signaling pathways involving \u03b2-catenin. Exp Cell Res 360(2):281\u2013291","journal-title":"Exp Cell Res"},{"issue":"11","key":"2466_CR118","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T et al (2014) Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 63(11):3891\u20133905","journal-title":"Diabetes"},{"key":"2466_CR119","doi-asserted-by":"crossref","first-page":"108667","DOI":"10.1016\/j.biopha.2019.108667","volume":"113","author":"ST Tang","year":"2019","unstructured":"Tang ST et al (2019) Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP\/PKA mediated down-regulation of MLC phosphorylation. Biomed Pharmacother 113:108667","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"2466_CR120","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/iub.2046","volume":"71","author":"W Yue","year":"2019","unstructured":"Yue W et al (2019) The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life 71(9):1347\u20131354","journal-title":"IUBMB Life"},{"issue":"3","key":"2466_CR121","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/JME-15-0264","volume":"56","author":"Y Feng","year":"2016","unstructured":"Feng Y et al (2016) Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation. J Mol Endocrinol 56(3):189\u2013199","journal-title":"J Mol Endocrinol"},{"key":"2466_CR122","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fphar.2019.00411","volume":"10","author":"B Xie","year":"2019","unstructured":"Xie B et al (2019) Geniposide alleviates glucocorticoid-Induced inhibition of osteogenic differentiation in MC3T3-E1 cells by ERK Pathway. Front Pharmacol 10:411","journal-title":"Front Pharmacol"},{"key":"2466_CR123","doi-asserted-by":"crossref","unstructured":"Deng Q et al (2019) Activation of hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via Wnt\/beta-Catenin. Elife, 8","DOI":"10.7554\/eLife.50208"},{"key":"2466_CR124","doi-asserted-by":"crossref","unstructured":"Molagoda IMN et al (2019) Fermented Oyster Extract promotes osteoblast differentiation by activating the Wnt\/\u03b2-Catenin signaling pathway, leading to bone formation. Biomolecules, 9(11)","DOI":"10.3390\/biom9110711"},{"issue":"4","key":"2466_CR125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","volume":"6","author":"J Meng","year":"2016","unstructured":"Meng J et al (2016) Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through \u03b2-Catenin. Stem Cell Rep 6(4):579\u2013591","journal-title":"Stem Cell Rep"},{"issue":"4","key":"2466_CR126","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","volume":"292","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA 292(4):490\u2013495","journal-title":"JAMA"},{"issue":"3","key":"2466_CR127","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1096\/fj.201901550R","volume":"34","author":"B Yang","year":"2020","unstructured":"Yang B et al (2020) Amyloid \u03b2 peptide promotes bone formation by regulating Wnt\/\u03b2-catenin signaling and the OPG\/RANKL\/RANK system. Faseb j 34(3):3583\u20133593","journal-title":"Faseb j"},{"issue":"1","key":"2466_CR128","doi-asserted-by":"crossref","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","volume":"7","author":"R Dankner","year":"2024","unstructured":"Dankner R et al (2024) Glucagon-like Peptide-1 receptor agonists and pancreatic Cancer risk in patients with type 2 diabetes. JAMA Netw Open 7(1):e2350408","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2466_CR129","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J et al (2023) GLP-1 receptor agonists and the risk of thyroid Cancer. Diabetes Care 46(2):384\u2013390","journal-title":"Diabetes Care"},{"issue":"2","key":"2466_CR130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","volume":"66","author":"C Cao","year":"2019","unstructured":"Cao C, Yang S, Zhou Z (2019) GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66(2):157\u2013165","journal-title":"Endocrine"},{"key":"2466_CR131","first-page":"p924168","volume":"2012","author":"WY Chiu","year":"2012","unstructured":"Chiu WY, Shih SR, Tseng CH (2012) A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer. Exp Diabetes Res 2012:p924168","journal-title":"Exp Diabetes Res"},{"key":"2466_CR132","doi-asserted-by":"crossref","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z et al (2022) GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS. Front Pharmacol 13:925377","journal-title":"Front Pharmacol"},{"issue":"2","key":"2466_CR133","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","volume":"46","author":"CA Thompson","year":"2023","unstructured":"Thompson CA, Sturmer T (2023) Putting GLP-1 RAs and thyroid Cancer in Context: additional evidence and remaining doubts. Diabetes Care 46(2):249\u2013251","journal-title":"Diabetes Care"},{"key":"2466_CR134","doi-asserted-by":"crossref","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","volume":"385","author":"B Pasternak","year":"2024","unstructured":"Pasternak B et al (2024) Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study. BMJ 385:e078225","journal-title":"BMJ"},{"issue":"10193","key":"2466_CR135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"4","key":"2466_CR136","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"19","key":"2466_CR137","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"10157","key":"2466_CR138","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529","journal-title":"Lancet"},{"issue":"10","key":"2466_CR139","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC et al (2021) Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med 385(10):896\u2013907","journal-title":"N Engl J Med"},{"key":"2466_CR140","doi-asserted-by":"crossref","unstructured":"Caparrotta TM et al (2021) Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Ther, 12(4): pp. 969\u2013989","DOI":"10.1007\/s13300-021-01021-1"},{"key":"2466_CR141","doi-asserted-by":"crossref","first-page":"927859","DOI":"10.3389\/fendo.2022.927859","volume":"13","author":"W Hu","year":"2022","unstructured":"Hu W et al (2022) Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a Meta-Analysis of Randomized controlled trials. Front Endocrinol (Lausanne) 13:927859","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2466_CR142","doi-asserted-by":"crossref","unstructured":"Lisco G et al (2023) Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? Endocr Connect, 12(11)","DOI":"10.1530\/EC-23-0257"},{"issue":"11","key":"2466_CR143","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1089\/thy.2016.0075","volume":"26","author":"HS Ahn","year":"2016","unstructured":"Ahn HS et al (2016) Thyroid Cancer Screening in South Korea increases detection of Papillary cancers with no impact on other subtypes or thyroid Cancer mortality. Thyroid 26(11):1535\u20131540","journal-title":"Thyroid"},{"issue":"6","key":"2466_CR144","doi-asserted-by":"crossref","first-page":"e0179387","DOI":"10.1371\/journal.pone.0179387","volume":"12","author":"S Jegerlehner","year":"2017","unstructured":"Jegerlehner S et al (2017) Overdiagnosis and overtreatment of thyroid cancer: a population-based temporal trend study. PLoS ONE 12(6):e0179387","journal-title":"PLoS ONE"},{"issue":"4","key":"2466_CR145","doi-asserted-by":"crossref","first-page":"e228722","DOI":"10.1001\/jamanetworkopen.2022.8722","volume":"5","author":"PH Dedhia","year":"2022","unstructured":"Dedhia PH et al (2022) Physician perspectives of overdiagnosis and overtreatment of low-risk papillary thyroid Cancer in the US. JAMA Netw Open 5(4):e228722","journal-title":"JAMA Netw Open"},{"key":"2466_CR146","doi-asserted-by":"crossref","first-page":"818816","DOI":"10.3389\/fpubh.2022.818816","volume":"10","author":"RA Nianogo","year":"2022","unstructured":"Nianogo RA, Arah OA (2022) Forecasting obesity and type 2 diabetes incidence and Burden: the ViLA-Obesity Simulation Model. Front Public Health 10:818816","journal-title":"Front Public Health"},{"issue":"12","key":"2466_CR147","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/obr.12321","volume":"16","author":"D Schmid","year":"2015","unstructured":"Schmid D et al (2015) Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev 16(12):1042\u20131054","journal-title":"Obes Rev"},{"key":"2466_CR148","doi-asserted-by":"crossref","first-page":"283","DOI":"10.12659\/MSM.892035","volume":"21","author":"J Ma","year":"2015","unstructured":"Ma J et al (2015) Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Monit 21:283\u2013291","journal-title":"Med Sci Monit"},{"key":"2466_CR149","doi-asserted-by":"crossref","first-page":"105085","DOI":"10.1016\/j.oraloncology.2020.105085","volume":"112","author":"MR Youssef","year":"2021","unstructured":"Youssef MR et al (2021) Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer - pooled results of 24 million cohorts. Oral Oncol 112:105085","journal-title":"Oral Oncol"},{"issue":"9","key":"2466_CR150","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00268-021-06193-2","volume":"45","author":"RJ O\u2019Neill","year":"2021","unstructured":"O\u2019Neill RJ et al (2021) Association of BMI with clinicopathological features of papillary thyroid Cancer: a systematic review and Meta-analysis. World J Surg 45(9):2805\u20132815","journal-title":"World J Surg"},{"issue":"5","key":"2466_CR151","first-page":"244","volume":"30","author":"LC Burrage","year":"2023","unstructured":"Burrage LC, McLeod DSA, Jordan SJ (2023) Obesity and thyroid cancer risk. Curr Opin Endocrinol Diabetes Obes 30(5):244\u2013251","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2466_CR152","doi-asserted-by":"crossref","first-page":"107040","DOI":"10.1016\/j.phrs.2023.107040","volume":"199","author":"ME Lunati","year":"2024","unstructured":"Lunati ME et al (2024) Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacol Res 199:107040","journal-title":"Pharmacol Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02466-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:42:30Z","timestamp":1738334550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02466-4"}},"subtitle":["Author list:"],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":152,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["2466"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02466-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}